Myeloma

Cynthia Chmielewski is a multiple myeloma hero for many around the world.

He dreams that this ever-growing body of knowledge will progressively improve the ability to understand and treat cancer; multiple myeloma has been at the center of this dream.

Some patients are at higher risk of infection, so it’s critical that they keep their care team up to date on any symptoms.

The past 20 years have brought great advances to advocacy groups, helping to improve patients’ quality of life. But more work is needed to raise awareness in underserved groups.

It is important that caregivers take care of not only the patient, but also themselves, as the diagnosis may affect their mental health.

From updates on clinical trials to a podcast where an oncology nurse shares how her son’s leukemia diagnosis changed her life, here are CURE®’s top blood cancer articles from the year 2022.

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

CURE®’s Multiple Myeloma Heroes® Award Program honors and gives thanks to those who have made it their mission to change the lives of patients with multiple myeloma.

Watch Dr. Dickran Kazandjian, from the Sylvester Comprehensive Cancer Center at the University of Miami, discuss available immunotherapy options during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. C. Ola Landgren and Dr. David Coffey answer questions about novel treatments and the role of a healthy immune system during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. David Coffey, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss the role of a healthy immune system during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. C. Ola Landgren, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss novel treatments for newly diagnosed patients during the CURE® Educated Patient® Multiple Myeloma Summit.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about clinical trials for patients with multiple myeloma.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about disparities in the multiple myeloma space.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the precursors to multiple myeloma, MGUS and smoldering myeloma.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the risk of infection for patients with multiple myeloma.

Tecvayli, which was recently approved for pretreated relapsed/refractory myeloma, is a “much more convenient” treatment option than CAR-T cell therapy, one expert said.

Aphexda was well tolerated and helped the majority of patients collect enough cells to go to transplant, study results showed.

Blenrep did not meet its progression-free survival endpoint in a phase 3 clinical trial for patients with relapsed or refractory multiple myeloma.

Stem cell transplants may cause dysgeusia — a disorder that alters a person’s taste —in some patients with multiple myeloma, which is a type of blood cancer. This disorder may have a domino effect on quality of life, although levels may return to normal a few months after the procedure, an expert said.

The FDA’s approval of Tecvayli was based on findings showing that 61.8% of patients with pretreated, relapsed/refractory myeloma responded to the drug.

In 2018, 18 trekkers completed an awe-inspiring hike of the Himalayan highlands to the doorstep of the world’s tallest mountain, Mount Everest, to raise awareness and funding for multiple myeloma, a type of blood cancer. Three of the climbers discuss a bond that hasn’t broken.

The FDA’s Oncologic Drugs Advisory Committee voted against the continued approval of Pepaxto for pretreated relapsed/refractory myeloma, based on survival data from a clinical trial.

Delivering Sarclisa via an under-the-skin injection may improve the quality of life of patients with pretreated relapsed, refractory multiple myeloma, according to recent research.

Firefighters and recovery workers exposed to the aftermath of 9/11 in New York City had a higher occurrence of MGUS, a condition which may progress to myeloma, according to recent research.

Long-term follow-up shows that treatment with Empliciti plus pomalidomide and dexamethasone continues to significantly increase survival rates in patients with relapsed or refractory multiple myeloma, a persistent cancer affecting white blood cells that may be resistant to treatment.

Lisa’s excellent fund of knowledge, experience in oncology, outstanding judgment and interest in learning all make her a truly outstanding clinician.

The use of five or more medicines — as well as some drugs that could be deemed inappropriate — may put older patients with cancer at a higher risk for complications, such as weakness.

Data from a clinical trial demonstrate a “clear clinical benefit” of using a CAR-T cell therapy in patients with multiple myeloma, according to the drugs manufacturer.

Findings from previous studies have shown that patients with blood cancers have been less likely to produce antibodies that protect them against COVID-19 after vaccination, but new research indicates that the booster shot may help.